HEALTHCARE
Global Autologous Stem Cell and Non-stem Cell Therapies Market - Industry Trends and Forecast to 2032
REPORT OVERVIEW
Global Autologous Stem Cell & Non-stem Cell Therapies Market, By Type (Autologous Stem Cell Therapies and Autologous Non-Stem Cell Therapies), Indication (Cancer Indications, Musculoskeletal Indications, Dermatological Indications, and Others), Source (T-Cells and Mesenchymal Stem Cells), End Use (Hospitals and Clinics, Long-term Care Facilities, and Specialty Care Centers), Region (North America, Europe, Asia-Pacific, South America, Middle East and Africa) – Industry Trends and Forecast to 2032.
Market Insights
The global Autologous Stem Cell & Non-stem Cell Therapies market size is valued to be USD xx million in 2023 and is expected to reach USD xx million by 2032, and it is expected to register a CAGR of xx% over the forecast period 2024-2032.
The global Autologous Stem Cell & Non-Stem Cell Therapies Market encompasses a diverse range of advanced treatment modalities. Autologous stem cell therapies involve using stem cells that are derived from the same individual who will receive the treatment. These cells are harvested from the patient's own body, processed, and then reintroduced to promote healing or regeneration. Non-stem cell therapies use various methods and materials to treat diseases or injuries, not involving stem cells. These therapies may focus on directly repairing or replacing damaged tissues, modulating the immune system, or using other biological or synthetic agents. These therapies offer innovative approaches to treating various diseases and conditions, with each segment contributing to the evolving landscape of modern medicine.
The respective global report analyses market trends, consumer behaviour and industry dynamics to guide towards entry into new markets with ease. Also, it assists in tailoring market specific and related products and services to meet the needs, preferences, and expectations of target audience by delving into their psychology. The report also specializes with comprehensive and extensive competitive analysis which offers useful insights into competitor strengths, weaknesses, opportunities, and threats. The respective report offers exclusive insights into the potential impact of disruptive developments and technologies that are expected to completely transform corporate operations. The context includes tailor-made research solutions to create a stronger footprint in their particular industries thereby offering dedicated customized solutions according to the client needs which helps in addressing unique business challenges with more simplified and efficient decision-making solutions.
Market Dynamics
DRIVERS
- Rising prevalence of chronic and degenerative conditions
- Growth in clinical trials and research
RESTRAINTS
- High cost of treatment
- Limited availability of suitable cells
OPPORTUNITIES
- Expansion into new therapeutic areas
- Increased investment and funding
CHALLENGES
- Patient-specific challenges
- Evolving regulatory and approval landscape
SEGMENTATION
- Type
- Autologous Stem Cell Therapies
- Autologous Non-Stem Cell Therapies
- Car T Cell Therapies
- Tumor Infiltrating Lymphocyte
- Indication
- Cancer Indications
- Musculoskeletal Indications
- Dermatological Indications
- Others
- Source
- T-Cells
- Mesenchymal Stem Cells
- End Use
- Hospitals and Clinics
- Long-term Care Facilities
- Specialty Care Centers
The respective global report is completely customizable specific to regions (North America, Europe, Asia-Pacific, South America, Middle East and Africa), countries, and segments as per the client requirements.
REGIONAL SEGMENTATION
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- The Netherlands
- Belgium
- Turkey
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Singapore
- Malaysia
- Australia
- Thailand
- Philippines
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Chile
- Colombia
- Rest of South America
- Middle East and Africa
- Kingdom of Saudi Arabia
- South Africa
- U.A.E.
- Egypt
- Rest of Middle East and Africa
KEY MARKET PLAYERS
- Bristol-Myers Squibb Company
- Green Cross Holdings Co., Ltd.
- IASO Biotherapeutics
- ImmunoACT
- Tegoscience
- healiva SA
- Novartis AG
- Vericel Corporation
- Johnson & Johnson
- APAC Biotech
Table OF CONTENTS
- SECTION 1 - INTRODUCTION
- 1.1 Taxonomy
- 1.2 Market Overview
- 1.3 Currency and Limitations
- 1.3.1 Currency
- 1.3.2 Limitations
- 1.4 Key Competitors
- SECTION 2 - RESEARCH METHODOLOGY
- 2.1 Research Approach
- 2.2 Data Collection and Validation
- 2.2.1 Secondary Research
- 2.2.2 Primary Research
- 2.3 Market Assessment
- 2.3.1 Market Size Estimation
- 2.3.2 Bottom-up Approach
- 2.3.3 Top-down Approach
- 2.3.4 Growth Forecast
- 2.4 Market Study Assumptions
- 2.5 Data Sources
- SECTION 3 - EXECUTIVE SUMMARY
- 3.1 Global Autologous Stem Cell & Non-stem Cell Therapies Market, by Type
- 3.2 Global Autologous Stem Cell & Non-stem Cell Therapies Market, by Indication
- 3.3 Global Autologous Stem Cell & Non-stem Cell Therapies Market, by Source
- 3.4 Global Autologous Stem Cell & Non-stem Cell Therapies Market, by End Use
- 3.5 Global Autologous Stem Cell & Non-stem Cell Therapies Market, by Geography
- 3.6 Market Position Grid
- SECTION 4 - PREMIUM INSIGHTS
- 4.1 Regulatory Framework
- 4.1.1 Standards
- 4.1.2 Regulatory Landscape
- 4.2 Value Chain Analysis
- 4.3 Supply Chain Analysis
- 4.4 COVID-19 Impact
- 4.5 Russia-Ukraine War Impact
- 4.6 PORTER's Five Force Analysis
- 4.7 PESTLE Analysis
- 4.8 SWOT Analysis
- 4.9 Go to Market Strategy
- 4.10 Opportunity Orbit
- 4.11 Multivariate Modelling
- 4.12 Pricing Analysis
- SECTION 5 - MARKET DYNAMICS
- 5.1 Trends
- 5.1.1 Patient and provider awareness
- 5.1.2 Personalized medicine
- 5.1.3 Trend 3
- 5.2 Drivers
- 5.2.1 Rising prevalence of chronic and degenerative conditions
- 5.2.2 Growth in clinical trials and research
- 5.2.3 Driver 3
- 5.2.4 Driver 4
- 5.3 Restraints
- 5.3.1 High cost of treatment
- 5.3.2 Limited availability of suitable cells
- 5.3.3 Restraint 3
- 5.4 Opportunities
- 5.4.1 Expansion into new therapeutic areas
- 5.4.2 Increased investment and funding
- 5.4.3 Opportunity 3
- 5.4.4 Opportunity 4
- 5.5 Challenges
- 5.5.1 Patient-specific challenges
- 5.5.2 Evolving regulatory and approval landscape
- 5.5.3 Challenge 3
- SECTION 6 - GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY TYPE
- 6.1 Type Summary
- 6.2 Market Attractive Index
- 6.3 Global Autologous Stem Cell & Non-stem Cell Therapies Market, by Type (2019-2032)
- SECTION 7 - GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY INDICATION
- 7.1 Indication Summary
- 7.2 Market Attractive Index
- 7.3 Global Autologous Stem Cell & Non-stem Cell Therapies Market, by Indication (2019-2032)
- SECTION 8 - GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY SOURCE
- 8.1 Source Summary
- 8.2 Market Attractive Index
- 8.3 Global Autologous Stem Cell & Non-stem Cell Therapies Market, by Source (2019-2032)
- SECTION 9 - GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY END USE
- 9.1 End Use Summary
- 9.2 Market Attractive Index
- 9.3 Global Autologous Stem Cell & Non-stem Cell Therapies Market, by End Use (2019-2032)
- SECTION 10 - GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, BY GEOGRAPHY
- 10.1 Regional Summary
- 10.2 Market Attractive Index
- 10.3 Global Autologous Stem Cell & Non-stem Cell Therapies Market, by Geography (2019-2032)
- SECTION 11 - NORTH AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET
- 11.1 North America Summary
- 11.2 Market Attractive Index
- 11.3 North America Autologous Stem Cell & Non-stem Cell Therapies Market, by Type (2019-2032)
- 11.4 North America Autologous Stem Cell & Non-stem Cell Therapies Market, by Indication (2019-2032)
- 11.5 North America Autologous Stem Cell & Non-stem Cell Therapies Market, by Source (2019-2032)
- 11.6 North America Autologous Stem Cell & Non-stem Cell Therapies Market, by End Use (2019-2032)
- 11.7 North America Autologous Stem Cell & Non-stem Cell Therapies Market, by Country (2019-2032)
- 11.7.1 U.S.
- 11.7.2 Canada
- 11.7.3 Mexico
- 11.7.4 Rest of North America
- SECTION 12 - EUROPE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET
- 12.1 Europe Summary
- 12.2 Market Attractive Index
- 12.3 Europe Autologous Stem Cell & Non-stem Cell Therapies Market, by Type (2019-2032)
- 12.4 Europe Autologous Stem Cell & Non-stem Cell Therapies Market, by Indication (2019-2032)
- 12.5 Europe Autologous Stem Cell & Non-stem Cell Therapies Market, by Source (2019-2032)
- 12.6 Europe Autologous Stem Cell & Non-stem Cell Therapies Market, by End Use (2019-2032)
- 12.7 Europe Autologous Stem Cell & Non-stem Cell Therapies Market, by Country (2019-2032)
- 12.7.1 Germany
- 12.7.2 U.K.
- 12.7.3 France
- 12.7.4 Italy
- 12.7.5 Spain
- 12.7.6 Russia
- 12.7.7 The Netherlands
- 12.7.8 Belgium
- 12.7.9 Turkey
- 12.7.10 Rest of Europe
- SECTION 13 - ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET
- 13.1 Asia-Pacific Summary
- 13.2 Market Attractive Index
- 13.3 Asia-Pacific Autologous Stem Cell & Non-stem Cell Therapies Market, by Type (2019-2032)
- 13.4 Asia-Pacific Autologous Stem Cell & Non-stem Cell Therapies Market, by Indication (2019-2032)
- 13.5 Asia-Pacific Autologous Stem Cell & Non-stem Cell Therapies Market, by Source (2019-2032)
- 13.6 Asia-Pacific Autologous Stem Cell & Non-stem Cell Therapies Market, by End Use (2019-2032)
- 13.7 Asia-Pacific Autologous Stem Cell & Non-stem Cell Therapies Market, by Country (2019-2032)
- 13.7.1 China
- 13.7.2 India
- 13.7.3 Japan
- 13.7.4 South Korea
- 13.7.5 Singapore
- 13.7.6 Malaysia
- 13.7.7 Australia
- 13.7.8 Thailand
- 13.7.9 Philippines
- 13.7.10 Rest of Asia-Pacific
- SECTION 14 - SOUTH AMERICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET
- 14.1 South America Summary
- 14.2 Market Attractive Index
- 14.3 South America Autologous Stem Cell & Non-stem Cell Therapies Market, by Type (2019-2032)
- 14.4 South America Autologous Stem Cell & Non-stem Cell Therapies Market, by Indication (2019-2032)
- 14.5 South America Autologous Stem Cell & Non-stem Cell Therapies Market, by Source (2019-2032)
- 14.6 South America Autologous Stem Cell & Non-stem Cell Therapies Market, by End Use (2019-2032)
- 14.7 South America Autologous Stem Cell & Non-stem Cell Therapies Market, by Country (2019-2032)
- 14.7.1 Brazil
- 14.7.2 Argentina
- 14.7.3 Chile
- 14.7.4 Colombia
- 14.7.5 Rest of South America
- SECTION 15 - MIDDLE EAST AND AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET
- 15.1 Middle East and Africa Summary
- 15.2 Market Attractive Index
- 15.3 Middle East and Africa Autologous Stem Cell & Non-stem Cell Therapies Market, by Type (2019-2032)
- 15.4 Middle East and Africa Autologous Stem Cell & Non-stem Cell Therapies Market, by Indication (2019-2032)
- 15.5 Middle East and Africa Autologous Stem Cell & Non-stem Cell Therapies Market, by Source (2019-2032)
- 15.6 Middle East and Africa Autologous Stem Cell & Non-stem Cell Therapies Market, by End Use (2019-2032)
- 15.7 Middle East and Africa Autologous Stem Cell & Non-stem Cell Therapies Market, by Country (2019-2032)
- 15.7.1 Kingdom of Saudi Arabia
- 15.7.2 South Africa
- 15.7.3 U.A.E.
- 15.7.4 Egypt
- 15.7.5 Rest of Middle East and Africa
- SECTION 16 - COMPANY SHARE ANALYSIS
- 16.1 Global Autologous Stem Cell & Non-stem Cell Therapies Market, Company Share Analysis
- 16.2 North America Autologous Stem Cell & Non-stem Cell Therapies Market, Company Share Analysis
- 16.3 Europe Autologous Stem Cell & Non-stem Cell Therapies Market, Company Share Analysis
- 16.4 Asia-Pacific Autologous Stem Cell & Non-stem Cell Therapies Market, Company Share Analysis
- SECTION 17 - COMPANY PROFILES
- 17.1 Bristol-Myers Squibb Company
- 17.1.1 Company Snapshot
- 17.1.2 Financial Overview
- 17.1.3 Product Portfolio
- 17.1.4 Recent Developments
- 17.2 Green Cross Holdings Co., Ltd.
- 17.2.1 Company Snapshot
- 17.2.2 Financial Overview
- 17.2.3 Product Portfolio
- 17.2.4 Recent Developments
- 17.3 IASO Biotherapeutics
- 17.3.1 Company Snapshot
- 17.3.2 Financial Overview
- 17.3.3 Product Portfolio
- 17.3.4 Recent Developments
- 17.4 ImmunoACT
- 17.4.1 Company Snapshot
- 17.4.2 Financial Overview
- 17.4.3 Product Portfolio
- 17.4.4 Recent Developments
- 17.5 Tegoscience
- 17.5.1 Company Snapshot
- 17.5.2 Financial Overview
- 17.5.3 Product Portfolio
- 17.5.4 Recent Developments
- 17.6 Healiva SA
- 17.6.1 Company Snapshot
- 17.6.2 Financial Overview
- 17.6.3 Product Portfolio
- 17.6.4 Recent Developments
- 17.7 Novartis AG
- 17.7.1 Company Snapshot
- 17.7.2 Financial Overview
- 17.7.3 Product Portfolio
- 17.7.4 Recent Developments
- 17.8 Vericel Corporation
- 17.8.1 Company Snapshot
- 17.8.2 Financial Overview
- 17.8.3 Product Portfolio
- 17.8.4 Recent Developments
- 17.9 Johnson & Johnson
- 17.9.1 Company Snapshot
- 17.9.2 Financial Overview
- 17.9.3 Product Portfolio
- 17.9.4 Recent Developments
- 17.10 APAC Biotech
- 17.10.1 Company Snapshot
- 17.10.2 Financial Overview
- 17.10.3 Product Portfolio
- 17.10.4 Recent Developments
- SECTION 18 - RELATED REPORTS
- SECTION 19 - DISCLAIMER
RESEARCH METHODOLOGY
The research methodology employed in Uniprism Market Research involves four basic steps namely research and data collection, data pre-processing, modeling and forecasting, quality assurance and output.
RESEARCH AND DATA COLLECTION
A tripod model research technique is followed for research and data collection in which various approaches such as primary research, secondary research, and product mapping are considered.
Primary research basically involves the process of conducting personalized interviews with market related professionals of major market players, investors, distributors, vendors and many more.
The secondary research include data published by government, annual reports, press releases, investor presentations of companies, white papers, certified publications, annual manufacturing limit of the respective industries related to the market, production consumption analysis of certain products respective to the market and many more.
Below mention are few of the sources which we have considered while estimating the market size:
For instance,
- Research articles published on Technium
- Science and MDPI
- Research publications by government approved associations and societies
Product mapping means the process of mapping the list of products that a key player contributes to the market as well as estimating the revenue of those products in order to define the Global Company share analysis of the respective Global Company in global, regional, and country level markets.
DATA PRE-PROCESSING
The term "data pre-processing" refers to the collection of procedures and methods used to clean, modify, and make ready for analysis the raw data gathered during research and data collection. The completion of this phase is necessary to guarantee that the data are reliable, consistent, and appropriate for statistical analysis and other data-driven tasks. The data pre-processing ensures that the information gathered from research and data collection is comparable and expressed in standard units, by the integration of missing data pointers and algorithmic approaches.
MODELING AND FORECASTING
The process of developing mathematical, statistical, or computational representations of real-world occurrences or relationships is known as modelling. These models are intended to replicate and explain market interactions, interdependence, and dynamics. These models are used by Uniprism Market Research to acquire a better knowledge of numerous market characteristics such as customer preferences, pricing elasticity, competition dynamics, and more. Depending on the individual study aims, many types of models are utilized, such as regression models, econometric models, decision tree models, and machine learning models.
Forecasting is the process of predicting future market conditions, trends, and occurrences using past data and models. Forecasting is used by Uniprism Market Research to estimate future sales, demand for products or services, market growth, and other important performance metrics. Forecasting accurately can assist organizations in making educated decisions about resource allocation, pricing, inventory management, and marketing tactics.
We create standardized bottom-up or top-down models that scale by leveraging data science and machine learning technology. All our market models consider the unique market characteristics of each country. Forecasting is based on major market indicators and a combination of traditional methodologies, such as exponential smoothing, time series analysis, regression analysis, and more modern techniques such as machine learning algorithms are all forecasting methodologies. The method chosen is determined on the nature of the data and the specific forecasting aims.
QUALITY ASSURANCE AND OUTPUT
Quality assurance and output involves the process of validation, adjustments, further publications of key market indicators. Extensive plausibility and consistency tests are performed on derived time series to ensure the high degree of quality of our market analysis. This quality assurance procedure also includes rigorous inspection, validation, and editing by an experienced management team to assure the dependability of the published data.